Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Paul Sabatier University EA- |
RCV000207371 | SCV000259111 | likely benign | Anophthalmia-microphthalmia syndrome | 2013-01-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002517389 | SCV003021104 | uncertain significance | not provided | 2024-10-22 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with glutamine, which is neutral and polar, at codon 2654 of the FAT4 protein (p.Lys2654Gln). This variant is present in population databases (rs760398912, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with FAT4-related conditions. ClinVar contains an entry for this variant (Variation ID: 221915). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt FAT4 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Breakthrough Genomics, |
RCV002517389 | SCV005256159 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Fulgent Genetics, |
RCV005025338 | SCV005659957 | uncertain significance | Van Maldergem syndrome 2; Hennekam lymphangiectasia-lymphedema syndrome 2 | 2024-03-07 | criteria provided, single submitter | clinical testing |